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Abstract
Introduction: Chemotherapy Induced neutropenia is a frequent and serious complication of
cytotoxic cancer treatment.
Granulocyte colony stimulating factors (G-CSF) are frequently used to counter neutropenia,
attempt rapid recovery of patients and allow for continuation of treatment without compromise
on dose, especially in curative malignancies. Generally regarded as safe, G-CSF use has been very
rarely reported to have resulted in serious side effects, such as, splenic rupture.
Case presentation: We are reporting a case of a twenty years old man, who was being treated
for T cell acute lymphoblastic leukemia and received colony stimulating factors for treatment of
severe neutropenia and suffered from splenic rupture, He was treated with splenectomy.
Conclusion: Although extremely rare, splenic rupture can be a serious and sometimes life
threatening complication of high dose colony stimulating factors therapy.

Introduction
One of the most serious toxicity of chemotherapy is neutropenia, a complication that leads to infection, hospitalization, and even death. Dose reduction in subsequent
cycles is also one of the compromise which has to be
made in anticipation of troublesome neutropenia[1]. GCSF therapy promote white blood cell (WBC) proliferation, maturation and functional capacity [2], they are
widely used to treat myelosupression caused by chemotherapy. By their effect of reducing the duration and severity of neutropenia, G-CSF use allows for continuation of
cytotoxic chemotherapy, that is, in order to obtain superior long term results in various cancers[3]. The results of

using G-CSF in primary prophylaxis for neutropenia are
promising[4], however their effectiveness in treatment of
established neutropenia remains controversial[5]. G-CSF
use is the cornerstone of therapy, for hematopoietic stem
cell mobilization for stem cell transplantation[3]. Therapy
with G-CSF is generally regarded as safe, as side effects
with doses as high as 600 μg/day, in healthy volunteers
have been tolerated safely. Therapy induced high WBC
counts tend to abate within 48 hours of withdrawal [6].
Side effects from long-term use as in patients with congenital neutropenia have also been regarded as generally safe
with need of stopping therapy arising rarely if ever[7].
Myocardial infarction, stroke and splenic rupture are
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some of the rare side effects of high dose G-CSF therapy.
There are few reported cases of splenic rupture secondary
to use of G-CSF so far, most of the reported patients were
either healthy donors of stem cell transplant patients or
patients undergoing peripheral blood stem cell mobilization for transplant (PBSCT) [2].
We here in report a case of a young patient suffering from
T-cell lymphoblastic lymphoma, who received G-CSF as
secondary prophylaxis and unfortunately suffered from
splenic rupture.

Case report
A 20 years old gentleman was being treated for Acute T cell
lymphoblastic lymphoma with hyper-CVAD regimen, the
therapy consists of Cyclophosphomide, vincristine, doxorubicin and dexamethasone alternating with high dose
methotraxate and cytarabine[8]. The patient suffered from
severe neutropenia after the first cycle of therapy and
required treatment with G-CSF prior to second, with the
intention to obtain full benefit of chemotherapy and not
compromising on dose. When followed in clinic he
showed a low white cell count with an absolute neutrophil count (ANC) of200 cells/microL on day 11 after
cycle 2 despite being on G-CSF 300 μg/day for 9 days. He
was advised to double the dose of G-CSF to 600 μg/day
and instructed to return with a complete blood count in
three days. About 10 days later he came to emergency
room complaining of severe and sharp left upper quadrant pain radiating to shoulder. His white cell count was >
140 × 10^9/l. A CT scan was obtained in the emergency
room (FIG 1) which showed splenomegaly with high density fluid noted around the spleen and pelvic region most
likely representing hemoperitoneum. There was an irregularity noted posteriorly with in the spleen and the location
of high density fluid raised the possibility of splenic rupture. Patient was initially treated with intravenous hydration and pain control, G-CSF was stopped. He under went
successful splenectomy two days later, histopathology of
which confirmed splenic rupture, splenic engorgement
and evidence of extramedullary hemopoiesis (Fig 2).
Patient's counts returned to < 14 × 109/l, and he was discharged uneventfully. He is currently completing his treatment with remaining cycles of hyper-CVAD regimen.

Discussion
Treatment with G-CSF is commonly practiced in patients
undergoing neutropenia secondary to chemotherapy for
cancers. It is generally considered safe and effective, while
many patients have derived benefits of therapy with GCSF, developing less infection, less antibiotic use and
shorter hospital stay, some suffer from minor self limited
side effects as well [7]. Prophylactic G-CSF use is recommended when using a chemotherapy regimen associated
with a risk of febrile neutropenia in > 20% patients, as is,
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its use in situations where dose-dense or dose-intense
chemotherapy strategies have survival benefit [1]. Uninterrupted G-CSF therapy is recommended in patients
undergoing treatment with hyper-CVAD until the white
cell count has recovered to 3.0 × 109/L[8]. There have
been case reports of splenic rupture in healthy donors of
PBSCT patients or patients themselves undergoing mobilization. Two of such patients have reportedly died as a
result while the rest were managed successfully with
splenectomy [2,9]. Case reports appearing in literature
following prophylactic G-CSF use are extremely rare[10].
To the best of our knowledge this is a rare case where GCSF induced splenic rupture has been reported in patient
suffering from acute lymphoblastic lymphoma. The
patient presented with acute onset left sided pain without
any history of trauma. He uninterruptedly took G-CSF for
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writing, literature search, reviewing the document and
coordination with the patient. WAM was the radiologist
involved in diagnosis and contributed in literature search.
RI was the pathologist involved in diagnosis, reviewing
the article and suggesting changes. All authors read the
paper and approved the final manuscript.
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about 20 days, with a dose of 5 μg/kg for the first ten days
followed by 10 μg/kg during the remaining ten. Splenic
rupture can be rationalized on the basis of extramedullary
myelopoies leading to parenchymal congestion.
Splenomegaly is seen in almost all PBSCT donors receiving G-CSF, regardless of age, sex or race. With a mean size
10.9 ± 2.0 cm before G-CSF to 12.3 ± 2.1 cm on the day of
aphaeresis [11]. PBSCT healthy donors receive G-CSF with
a dose 10 μg/kg for 5 days only, our patient received on an
average a dose of 7.5 μg/kg/day for more than 20 days,
which placed him at a high risk for splenic rupture secondary to splenic congestion, despite of the protection
offered by the fact that he was neutropenic to begin with
(unlike healthy donors). The Rare but serious complication of G-CSF therapy needs to be addressed carefully
while treating patients with full intention therapy and a
close follow up should be insisted to save the patients
form unnecessary hospitalization, cost, morbidity and
possibly mortality.

3. RI from the department of pathology: the Aga Khan
University hospital, Karachi, Pakistan.

References
1.

2.

3.
4.

5.

6.

7.

Consent

8.

"Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal."

9.

Competing interests

10.

The authors declare that they have no competing interests.

Authors' contributions
NM: participated in literature search, manuscript writing
and review of document. AJS: participated in manuscript

11.

Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M,
et al.: EORTC guidelines for the use of granulocyte-colony
stimulating factor to reduce the incidence of chemotherapyinduced febrile neutropenia in adult patients with lymphomas and solid tumours. European journal of cancer 2006,
42(15):2433-53.
Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A: Spontaneous splenic rupture in a healthy allogeneic donor of
peripheral-blood stem cell following the administration of
granulocyte colony-stimulating factor (g-csf). A case report
and review of the literature. Haematologica 2006, 91(5
Suppl):ECR08.
Lionne-Huyghe P, Kuhnowski F, Coiteux V, Bauters F, Morschhauser
F: [Indications of G-CSF administration in hematologic disorders]. Bulletin du cancer 93(5):453-62.
Kuderer NM, Dale DC, Crawford J, Lyman GH: Impact of primary
prophylaxis with granulocyte colony-stimulating factor on
febrile neutropenia and mortality in adult cancer patients
receiving chemotherapy: a systematic review. J Clin Oncol
25(21):3158-67.
Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C,
et al.: Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with
meta-analysis. Support Care Cancer 2002, 10(3):181-8.
Borleffs JC, Bosschaert M, Vrehen HM, Schneider MM, van Strijp J,
Small MK, et al.: Effect of escalating doses of recombinant
human granulocyte colony-stimulating factor (filgrastim) on
circulating neutrophils in healthy subjects. Clinical therapeutics
1998, 20(4):722-36.
Freedman MH: Safety of long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia. Current opinion in hematology 1997, 4(3):217-24.
Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al.:
Results of treatment with hyper-CVAD, a dose-intensive
regimen, in adult acute lymphocytic leukemia. J Clin Oncol
2000, 18(3):547-61.
O'Malley DP, Whalen M, Banks PM: Spontaneous splenic rupture
with fatal outcome following G-CSF administration for myelodysplastic syndrome. American journal of hematology 2003,
73(4):294-5.
Watring NJ, Wagner TW, Stark JJ: Spontaneous splenic rupture
secondary to pegfilgrastim to prevent neutropenia in a
patient with non-small-cell lung carcinoma. The American journal of emergency medicine 2007, 25(2):247-8.
Stroncek D, Shawker T, Follmann D, Leitman SF: G-CSF-induced
spleen size changes in peripheral blood progenitor cell
donors. Transfusion 2003, 43(5):609-13.

Page 3 of 3
(page number not for citation purposes)

